Abstract
Cefoperazone is a semisynthetic cephalosporin of the 3rd generation (cefobid, Pfizer, USA). It was used in monotherapy of 12 oncological patients during ++post-cytostatic aplasia of the bone marrow and peripheral pancytopenia after bone marrow transplantation. The results were favourable in 67 per cent of the patients: the body temperature normalized and no signs of any infection were evident. In 25 per cent of the patients the monotherapy failed and it was necessary to combine cefoperazone with aminoglycosides. Therefore, cefoperazone proved to be an efficient antibacterial drug, whose use was possible in the monotherapy of oncological patients after transplantation of the bone marrow.
MeSH terms
-
Adolescent
-
Adult
-
Anemia, Aplastic / chemically induced
-
Anemia, Aplastic / surgery*
-
Antineoplastic Agents / adverse effects*
-
Antineoplastic Agents / therapeutic use
-
Bone Marrow Transplantation / adverse effects*
-
Cefoperazone / administration & dosage*
-
Child
-
Child, Preschool
-
Female
-
Hodgkin Disease / blood
-
Hodgkin Disease / drug therapy*
-
Humans
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
-
Leukemia, Myeloid, Acute / blood
-
Leukemia, Myeloid, Acute / drug therapy*
-
Leukemia, Myeloid, Acute / pathology
-
Male
-
Middle Aged
-
Pancytopenia / chemically induced
-
Pancytopenia / surgery*
-
Postoperative Care
-
Surgical Wound Infection / prevention & control*
Substances
-
Antineoplastic Agents
-
Cefoperazone